Sun Pharma's $12bn Organon bet doubles down on women's health

India's largest drugmaker is acquiring US-listed Organon for $14 per share, creating a $12.4 billion combined entity that positions Sun Pharma as a top-25 global pharmaceutical company. The all-cash deal assumes $8.6 billion in Organon debt while targeting the fastest-growing segments: biosimilars and women's health products across 100-plus markets. Organon's 30.7% EBITDA margins and established US presence offer Sun Pharma the scale to compete with Western giants, though integration risks loom large given the debt load. This marks India's biggest overseas pharma acquisition since independence, signalling confidence in demographic trends driving women's healthcare demand.